ABIOTI HEPARINANTAGONISTEN

Abiotic heparin antagonists

The present invention relates to heparin-binding calixarene compounds of general Formula (I) in which R, R₁, L and n have the meanings indicated in the description and their use in the biomedical field.

ABIOTISCHE HEPARINANTAGONISTEN

Cryogel for the removal of heparins and heparinoids from aqueous solutions, physiological solutions and biological fluids, preparation process and uses thereof

The object of the present invention is a new cryopolymerization process that provides crosslinked polymeric materials in the form of a macroporous gel (cryogel) capable of sequestering (neutralize) the anticoagulant heparin, its low molecular weight derivatives (LMWH and ULMWH) and heparinoids, from aqueous solutions, physiological solutions and biological fluids, such as whole blood, serum and plasma. A further object of the invention are also crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtained by the cryopolymerization process of the invention that, thanks to said specific process, result to be comprised of varying proportions of HEMA and HEMA-R monomers. The molar ratio between the components (HEMA/HEMA-R) may vary between 99.9% HEMA:0.1% HEMA-R and 0.1% HEMA:99.9% HEMA-R. Object of the invention is also the use of crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtainable by the cryopolymerization process of the invention for the construction of filters, membranes or devices for the treatment of biological fluids. A further object of the invention are therefore filters, membranes, or devices for the treatment of biological fluids which comprise materials obtained by the cryopolymerization process of the invention.

Abiotic heparin antagonists

The present invention relates to heparin-binding calixarene compounds of general Formula (I) in which R, R1, L and n have the meanings indicated in the description and their use in the biomedical field.

Cryogel for the Removal of Heparins and Heparinoids from Aqueous Solutions, Physiological Solutions and Biological Fluids, Preparation Process and Uses Thereof

The object of the present invention is a new cryopolymerization process that allows to obtain crosslinked polymeric materials in the form of a macroporous gel (cryogel) capable of sequestering (neutralize) the anticoagulant heparin, its low molecular weight derivatives (LMWH and ULMWH) and heparinoids, from aqueous solutions, physiological solutions and biological fluids, such as whole blood, serum and plasma. 2. Process for the synthesis of crosslinked polymeric materials in the form of a macroporous gel according to claim 1 , wherein the solution is an aqueous solution claim 1 , or it is comprised of a polar organic solvent claim 1 , preferably selected from dimethylsulfoxide claim 1 , dioxane claim 1 , acetamide claim 1 , tert-butyl alcohol claim 1 , or a mixture thereof claim 1 , more preferably being an aqueous solution.3. Process for the synthesis of crosslinked polymeric materials in the form of a macroporous gel according to any one of the preceding claims claim 1 , wherein named Q the ratio between HEMA moles and HEMA-R moles claim 1 , preferred values for Q are 3 claim 1 , 1 or 0.33.4. Process for the synthesis of crosslinked polymeric materials in the form of a macroporous gel according to any one of the preceding claims claim 1 , wherein an amount of crosslinking agent comprised in the range between 1/10 and ⅓ by moles is used claim 1 , based on the sum of the monomers used by moles.5. Process for the synthesis of crosslinked polymeric materials in the form of a macroporous gel according to any one of the preceding claims claim 1 , wherein the pH of the solution containing the HEMA and HEMA-R monomers claim 1 , and the crosslinking agent is comprised in the range between 7.0 and 8.0.6. Process for the synthesis of crosslinked polymeric materials in the form of a macroporous gel according to any one of the preceding claims claim 1 , wherein the sum of HEMA and HEMA-R monomers is comprised in the range from 5% to 50% by weight claim 1 , based on the weight ...

Abiotic heparin antagonists

The present invention relates to heparin-binding calixarene compounds of general Formula (I) in which R, R1, L and n have the meanings indicated in the description and their use in the biomedical field.

Cryogel for the removal of heparins and heparinoids from aqueous solutions, physiological solutions and biological fluids, preparation process and uses thereof

EPARINE ABIOTIC ANTAGONISTICS.

N-alkyl-d-glucamine based macroporous polymeric cryogel for sequestering and/or removing toxic contaminants

The disclosure relates to N-alkyl-D-glucamine based macroporous polymeric cryogels with three-dimensional structure and with interconnected pores, which are used for sequestering and/or removing toxic contaminants, such as toxic metalloids and/or toxic heavy metals, for example from water and/or soil and the method for the preparation of said -alkyl-D-glucamine based macroporous polymeric cryogels.

Abiotische heparinantagonisten